Literature DB >> 21896011

Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins.

Raymond J Ning1, Xue Q Xu, Kwok H Chan, Alan K S Chiang.   

Abstract

T cells simultaneously producing multiple cytokines and possessing cytotoxic capacity termed polyfunctional cells (PFCs) are increasingly recognized as the immune correlate of protection against pathogenic viruses. We investigated co-expression of four cytokines (interferon-γ, macrophage inflammatory protein 1-α, tumour necrosis factor-α and interleukin-2) and degranulation capacity (CD107a surface expression) of Epstein-Barr virus (EBV) -specific CD4(+) and CD8(+) T cells upon stimulation by overlapping peptides of EBV lytic (BZLF1) and latent (EBNA1, EBNA3 and LMP2) proteins, in 20 healthy Chinese long-term carriers. Two patients with post-transplant lymphoproliferative disorder (PTLD), who had impaired T-cell immunity, were studied for comparison. Both EBV-specific CD4(+) and CD8(+) PFCs were readily generated in long-term carriers and showed immunodominance hierarchies of latent proteins (EBNA1 > EBNA3/LMP2 and EBNA3 > LMP2 > EBNA1 for CD4(+) and CD8(+) T cells, respectively), as evidenced by a higher proportion of PFCs generated by immunodominant EBV proteins than by subdominant viral proteins. In contrast, the proportion of EBV-specific PFCs was markedly decreased in patients with PTLD. The EBV-specific PFCs produced more cytokine per cell than single-functional T cells and comprised different subsets. Five-functional CD4(+) and CD8(+) T cells were detected and four-functional CD4(+) T cells were mainly CD107a negative and expressed all four cytokines whereas four-functional CD8(+) T cells were mainly CD107a positive and expressed three of the four cytokines (interleukin-2-negative). We conclude that EBV-specific PFCs are generated in much higher proportions in the long-term carriers than in the patients with PTLD and maintain the immunodominant characteristics of the virus.
© 2011 The Authors. Immunology © 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21896011      PMCID: PMC3194224          DOI: 10.1111/j.1365-2567.2011.03476.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  35 in total

Review 1.  Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection.

Authors:  George Makedonas; Michael R Betts
Journal:  Springer Semin Immunopathol       Date:  2006-08-25

2.  Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major.

Authors:  Patricia A Darrah; Dipti T Patel; Paula M De Luca; Ross W B Lindsay; Dylan F Davey; Barbara J Flynn; Søren T Hoff; Peter Andersen; Steven G Reed; Sheldon L Morris; Mario Roederer; Robert A Seder
Journal:  Nat Med       Date:  2007-06-10       Impact factor: 53.440

Review 3.  T-cell quality in memory and protection: implications for vaccine design.

Authors:  Robert A Seder; Patricia A Darrah; Mario Roederer
Journal:  Nat Rev Immunol       Date:  2008-03-07       Impact factor: 53.106

4.  Detailed analysis of Epstein-Barr virus-specific CD4+ and CD8+ T cell responses during infectious mononucleosis.

Authors:  J Scherrenburg; E R W A N Piriou; N M Nanlohy; D van Baarle
Journal:  Clin Exp Immunol       Date:  2008-06-28       Impact factor: 4.330

Review 5.  Epstein-Barr virus and systemic lupus erythematosus.

Authors:  Judith A James; John B Harley; R Hal Scofield
Journal:  Curr Opin Rheumatol       Date:  2006-09       Impact factor: 5.006

Review 6.  Epstein-Barr virus and multiple sclerosis.

Authors:  Marco Salvetti; Gavin Giovannoni; Francesca Aloisi
Journal:  Curr Opin Neurol       Date:  2009-06       Impact factor: 5.710

7.  Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells.

Authors:  Sunil Kannanganat; Chris Ibegbu; Lakshmi Chennareddi; Harriet L Robinson; Rama Rao Amara
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

Review 8.  Epstein-Barr virus in autoimmune diseases.

Authors:  Eric Toussirot; Jean Roudier
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-10       Impact factor: 4.098

9.  Polyfunctional T cell responses are a hallmark of HIV-2 infection.

Authors:  Melody G Duvall; Melissa L Precopio; David A Ambrozak; Assan Jaye; Andrew J McMichael; Hilton C Whittle; Mario Roederer; Sarah L Rowland-Jones; Richard A Koup
Journal:  Eur J Immunol       Date:  2008-02       Impact factor: 5.532

Review 10.  Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.

Authors:  Andrew D Hislop; Graham S Taylor; Delphine Sauce; Alan B Rickinson
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

View more
  13 in total

1.  Epstein-Barr virus-specific CD8(+) T lymphocytes from diffuse large B cell lymphoma patients are functionally impaired.

Authors:  D Cárdenas; G Vélez; A Orfao; M V Herrera; J Solano; M Olaya; A M Uribe; C Saavedra; M Duarte; M Rodríguez; M López; S Fiorentino; S Quijano
Journal:  Clin Exp Immunol       Date:  2015-09-11       Impact factor: 4.330

2.  Age-associated Epstein-Barr virus-specific T cell responses in seropositive healthy adults.

Authors:  D Cárdenas Sierra; G Vélez Colmenares; A Orfao de Matos; S Fiorentino Gómez; S M Quijano Gómez
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

3.  CD4+ and CD8+ T-cell responses to latent antigen EBNA-1 and lytic antigen BZLF-1 during persistent lymphocryptovirus infection of rhesus macaques.

Authors:  R M Leskowitz; X Y Zhou; F Villinger; M H Fogg; A Kaur; P M Lieberman; F Wang; H C Ertl
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

4.  Measurement of CD8+ and CD4+ T Cell Frequencies Specific for EBV LMP1 and LMP2a Using mRNA-Transfected DCs.

Authors:  Dae-Hee Sohn; Hyun-Jung Sohn; Hyun-Joo Lee; Seon-Duk Lee; Sueon Kim; Seung-Joo Hyun; Hyun-Il Cho; Seok-Goo Cho; Suk-Kyeong Lee; Tai-Gyu Kim
Journal:  PLoS One       Date:  2015-05-29       Impact factor: 3.240

5.  Emergence of CD4+ and CD8+ Polyfunctional T Cell Responses Against Immunodominant Lytic and Latent EBV Antigens in Children With Primary EBV Infection.

Authors:  Janice K P Lam; K F Hui; Raymond J Ning; X Q Xu; K H Chan; Alan K S Chiang
Journal:  Front Microbiol       Date:  2018-03-07       Impact factor: 5.640

6.  Broad-Based CD4+ T Cell Responses to Influenza A Virus in a Healthy Individual Who Lacks Typical Immunodominance Hierarchy.

Authors:  Li Chen; Anjaleena Anthony; Sara Oveissi; Miaojuan Huang; Damien Zanker; Kun Xiao; Chao Wu; Quanming Zou; Weisan Chen
Journal:  Front Immunol       Date:  2017-04-03       Impact factor: 7.561

Review 7.  Human immunity against EBV-lessons from the clinic.

Authors:  Stuart G Tangye; Umaimainthan Palendira; Emily S J Edwards
Journal:  J Exp Med       Date:  2017-01-20       Impact factor: 14.307

8.  Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56dimNKG2A+KIR- NK Cells and Contributes to Suboptimal Control of EBV in Immunosuppressed Children With Post-transplant Lymphoproliferative Disorder.

Authors:  Janice K P Lam; Tarik Azzi; K F Hui; Aikha M G Wong; Donal McHugh; Nicole Caduff; K H Chan; Christian Münz; Alan K S Chiang
Journal:  Front Immunol       Date:  2020-06-17       Impact factor: 7.561

9.  A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.

Authors:  Graham S Taylor; Hui Jia; Kevin Harrington; Lip Wai Lee; James Turner; Kristin Ladell; David A Price; Manjit Tanday; Jen Matthews; Claudia Roberts; Ceri Edwards; Lesley McGuigan; Andrew Hartley; Steve Wilson; Edwin P Hui; Anthony T C Chan; Alan B Rickinson; Neil M Steven
Journal:  Clin Cancer Res       Date:  2014-08-14       Impact factor: 12.531

Review 10.  Epstein-Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency.

Authors:  Jean-Marie Carpier; Carrie L Lucas
Journal:  Front Immunol       Date:  2018-01-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.